Table 1.

Summary of pharmacology of CB₁/CB₂ receptor-independent relaxant responses to cannabinoids

Ligands	SR141716A	AM-251	O-1918	L-NAME	De-endothelization	PTX	FAAH inhibitors	APA + ChTx	IbTx	TRPV1 antagonism	αGA	pEC50 (μM)	Rmax, %	Vascular bed	Reference
AEA	Inhibition			No effect	No effect	Inhibition		No effect	No effect			6.3	95	RSMA	White and Hiley, 1997
AEA	Inhibition			No effect	Slight inhibition					Slight inhibition	Inhibition	6.2	94	RMA	Harris et al., 2002
AEA	Inhibition	Inhibition	Inhibition	No effect	Inhibition			Inhibition		Inhibition	Inhibition	5.7	89	RSMA	O'Sullivan et al., 2004
AEA	Inhibition	Inhibition	No effect	No effect	No effect			No effect		Inhibition	No effect	5.0	33	RMA	O'Sullivan et al., 2004
AEA									No effect				80	RMA	Yang et al., 2007
AEA	Inhibition	No effect			No effect		No effect		Inhibition	No effect	No effect	6.8	45	RCA	White et al., 2001
AEA										Inhibition		6.7	97	RSMA	White et al., 2001
AEA	No effect			Inhibition	Inhibition	Inhibition	Inhibition	No effect		No effect		5.9	51	RA	Herradon et al., 2007
AEA	No effect	No effect			No effect	Inhibition				No effect		5.9	22	RA	O'Sullivan et al., 2005b
AEA		No effect										5.2	90	HPA	Kozlowska et al., 2007
AEA		No effect	Inhibition	Inhibition	Inhibition		Inhibition	Inhibition		No effect		5	90	RPA	Baranowska-Kuczko et al., 2012
methAEA	Inhibition				Inhibition	Inhibition				Slight inhibition	No effect	0.6	80	RabA	Mukhopadhyay et al., 2002
Abn-CBD	Inhibition			No effect	Inhibition			Inhibition	No effect	No effect				RPIMAB	Jarai et al., 1999
Abn-CBD			Inhibition									3.0	107	RMA	Johns et al., 2007
Abn-CBD			Inhibition	No effect		Inhibition		Inhibition		No effect		6.7	93	RMA	Offertaler et al., 2003
Abn-CBD	Inhibition	Inhibition		No effect		No effect		Inhibition	No effect		No effect	6.2	93	RSMA	Ho and Hiley, 2003a
Abn-CBD		No effect	Inhibition	Inhibition	Inhibition		Inhibition	Inhibition		No effect		4.6	82	RPA	Baranowska-Kuczko et al., 2012
Abn-CBD			Inhibition			no effect						2		RMA	Milman et al., 2006
abn-cnd			Inhibition	No effect	Inhibition	Inhibition		Inhibition				4.8	110	HPA	Kozlowska et al., 2007
NAGly		No effect	Inhibition	Inhibition	Inhibition	Inhibition	No effect	Inhibition	Inhibition	No effect		5.8	88	RSMA	Parmar and Ho, 2010
ARA-S				Inhibition					Inhibition			4.9	84	RSMA	Parmar and Ho, 2010
ARA-S			Inhibition			No effect						0.55	95	RMA	Milman et al., 2006
ARA-S	No effect		No effect			Inhibition						1.2	60	RA	Milman et al., 2006
Oleamide	Inhibition	No effect	Inhibition	Inhibition	Inhibition	Inhibition		Inhibition		Inhibition		1.2	99	RSMA	Hoi and Hiley, 2006

Abn-CBD, abnormal cannabidiol; AEA, anandamide; APA + ChTx, apamin plus charybdotoxin; FAAH, fatty acid amide hydrolase; HPA, human pulmonary artery; IbTx, iberiotoxin; L-NAME, NG-Nitro-L-arginine methyl ester; RA, rat aorta; RCA, rat coronary artery; RPA, rat pulmonary artery; RSMA, rat small mesenteric artery; TRPV, transient receptor potential cation channel subfamily V.